Evidence map›Paper›PMID 40619373›Full record

Trial reportBMC gastroenterology2025

Endobiliary radiofrequency ablation in recurrence and unresectable Perihilar cholangiocarcinoma.

Apiwat Jareanrat, Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Theerawee Tipwaratorn, Anucha Ahooja, Watcharin Loilome, Piya Prajumwongs, Attapol Titapun

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Apiwat JareanratDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Vasin ThanasukarnDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Tharatip SrisukDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Vor LuviraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Theerawee TipwaratornDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Anucha AhoojaDepartment of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Watcharin LoilomeSystems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Piya PrajumwongsCholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.
Attapol TitapunDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. attati@kku.ac.th.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPalliative biliary stenting is the principal treatment for unresectable perihilar cholangiocarcinoma (pCCA) patients with jaundice. Endobiliary radiofrequency ablation (EBRFA) is a novel treatment used in combination with biliary stenting for CCA, aiming to prolong stent patency and patient survival. However, the evidence regarding its safety and efficacy in perihilar CCA remains limited. This study aims to investigate the safety of EBRFA and efficacy in terms of increasing stent patency and the patient's survival.

methodsPatients with unresectable perihilar CCA were prospectively randomized into 2 groups, including EBRFA with self-expandable metallic stent (SEMS) and SEMS alone. Stent patency time was recorded after stent implantation and until obstructive jaundice occurred. The median survival time (MST), median stent patency, and adverse event rate were analyzed and compared using the Log-rank test. The proportion comparisons of patient characteristics, preoperative testing, procedure detail, and morbidity in two methods were conducted by the Chi-square test.

resultOf a total of 39 patients who were diagnosed with pCCA and included in this study, 22 patients were in the EBRFA group and 17 patients were in the SEMS group. The procedure-related complication rate was not statistically significantly different between the EBRFA and the SEMS groups. There was no statistically significant difference in stent patency time between the EBRFA and SEMS groups (71 vs. 78 days, p-value = 0.809), and the OS of the EBRFA group had no statistically significant difference with the SEMS group (94 vs. 79 days, HR = 1.31, 95%CI: 0.66-2.58, p-value = 0.735).

conclusionThe EBRFA, when combined with SEMS placement, demonstrated procedural feasibility and acceptable outcomes as a potential palliative approach for patients with unresectable pCCA.

trial registrationTCTR20190704002.

Indexed as

Bile Duct NeoplasmsKlatskin TumorNeoplasm Recurrence, LocalRadiofrequency AblationAgedFemaleHumansMaleMiddle AgedPalliative CareProspective StudiesSelf Expandable Metallic StentsStentsTreatment OutcomeCholangiocarcinomaEndobiliary radiofrequency ablationKlatskin tumorMetallic biliary stentObstructive jaundicePalliative treatmentRandomized trialUnresectable treatment

Identifiers

PMID40619373
PMCPMC12232654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.